173 related articles for article (PubMed ID: 29843664)
1. Predictors of latent tuberculosis infection treatment completion in the US private sector: an analysis of administrative claims data.
Stockbridge EL; Miller TL; Carlson EK; Ho C
BMC Public Health; 2018 May; 18(1):662. PubMed ID: 29843664
[TBL] [Abstract][Full Text] [Related]
2. Tuberculosis Prevention in the Private Sector: Using Claims-Based Methods to Identify and Evaluate Latent Tuberculosis Infection Treatment With Isoniazid Among the Commercially Insured.
Stockbridge EL; Miller TL; Carlson EK; Ho C
J Public Health Manag Pract; 2018; 24(4):E25-E33. PubMed ID: 29084120
[TBL] [Abstract][Full Text] [Related]
3. Interferon gamma release assay tests are associated with persistence and completion of latent tuberculosis infection treatment in the United States: Evidence from commercial insurance data.
Stockbridge EL; Loethen AD; Annan E; Miller TL
PLoS One; 2020; 15(12):e0243102. PubMed ID: 33270737
[TBL] [Abstract][Full Text] [Related]
4. Factors Associated With Latent Tuberculosis Infection Treatment Failure Among Patients With Commercial Health Insurance-United States, 2005-2016.
Iqbal SA; Isenhour CJ; Mazurek G; Langer AJ; Chang MH; Truman BI
J Public Health Manag Pract; 2021 Jul-Aug 01; 27(4):E151-E161. PubMed ID: 31688742
[TBL] [Abstract][Full Text] [Related]
5. Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study.
Schein YL; Madebo T; Andersen HE; Arnesen TM; Dyrhol-Riise AM; Tveiten H; White RA; Winje BA
BMC Infect Dis; 2018 Nov; 18(1):587. PubMed ID: 30453946
[TBL] [Abstract][Full Text] [Related]
6. Better Completion of Pediatric Latent Tuberculosis Treatment Using 4 Months of Rifampin in a US-based Tuberculosis Clinic.
Gaensbauer J; Aiona K; Haas M; Reves R; Young J; Belknap R
Pediatr Infect Dis J; 2018 Mar; 37(3):224-228. PubMed ID: 28777204
[TBL] [Abstract][Full Text] [Related]
7. Private sector tuberculosis prevention in the US: Characteristics associated with interferon-gamma release assay or tuberculin skin testing.
Stockbridge EL; Miller TL; Carlson EK; Ho C
PLoS One; 2018; 13(3):e0193432. PubMed ID: 29590130
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the role of primary care physicians in the treatment of latent tuberculosis: a population study.
Rubinowicz A; Bartlett G; MacGibbon B; Greenaway C; Ronald L; Munoz M; Menzies D
Int J Tuberc Lung Dis; 2014 Dec; 18(12):1449-54. PubMed ID: 25517810
[TBL] [Abstract][Full Text] [Related]
9. Latent tuberculous infection in the United States and Canada: who completes treatment and why?
Hirsch-Moverman Y; Shrestha-Kuwahara R; Bethel J; Blumberg HM; Venkatappa TK; Horsburgh CR; Colson PW;
Int J Tuberc Lung Dis; 2015 Jan; 19(1):31-8. PubMed ID: 25519787
[TBL] [Abstract][Full Text] [Related]
10. A cross-sectional study of latent tuberculosis infection, insurance coverage, and usual sources of health care among non-US-born persons in the United States.
Annan E; Stockbridge EL; Katz D; Mun EY; Miller TL
Medicine (Baltimore); 2021 Feb; 100(7):e24838. PubMed ID: 33607853
[TBL] [Abstract][Full Text] [Related]
11. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
Sandul AL; Nwana N; Holcombe JM; Lobato MN; Marks S; Webb R; Wang SH; Stewart B; Griffin P; Hunt G; Shah N; Marco A; Patil N; Mukasa L; Moro RN; Jereb J; Mase S; Chorba T; Bamrah-Morris S; Ho CS
Clin Infect Dis; 2017 Oct; 65(7):1085-1093. PubMed ID: 28575208
[TBL] [Abstract][Full Text] [Related]
12. Latent tuberculosis treatment completion rates from prescription drug administrative data.
Plourde PJ; Basham CA; Derksen S; Schultz J; McCulloch S; Larcombe L; Kinew KA; Lix LM
Can J Public Health; 2019 Dec; 110(6):705-713. PubMed ID: 31297736
[TBL] [Abstract][Full Text] [Related]
13. Timing of treatment interruption among latently infected tuberculosis cases treated with a nine-month course of daily isoniazid: findings from a time to event analysis.
Séraphin MN; Hsu H; Chapman HJ; de Andrade Bezerra JL; Johnston L; Yang Y; Lauzardo M
BMC Public Health; 2019 Sep; 19(1):1214. PubMed ID: 31481046
[TBL] [Abstract][Full Text] [Related]
14. Treatment guidelines for latent tuberculosis infection.
;
Kekkaku; 2014 Jan; 89(1):21-37. PubMed ID: 24654427
[TBL] [Abstract][Full Text] [Related]
15. Latent TB infection treatment acceptance and completion in the United States and Canada.
Horsburgh CR; Goldberg S; Bethel J; Chen S; Colson PW; Hirsch-Moverman Y; Hughes S; Shrestha-Kuwahara R; Sterling TR; Wall K; Weinfurter P;
Chest; 2010 Feb; 137(2):401-9. PubMed ID: 19793865
[TBL] [Abstract][Full Text] [Related]
16. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
[TBL] [Abstract][Full Text] [Related]
17. Determinants of Latent Tuberculosis Treatment Acceptance and Completion in Healthcare Personnel.
Swift MD; Molella RG; Vaughn AIS; Breeher LE; Newcomb RD; Abdellatif S; Murad MH
Clin Infect Dis; 2020 Jul; 71(2):284-290. PubMed ID: 31552416
[TBL] [Abstract][Full Text] [Related]
18. Completion rate of latent tuberculosis infection treatment in patients aged 65 years and older.
Noh CS; Kim HI; Choi H; Kim Y; Kim CH; Choi JH; Hyun IG; Baek MS
Respir Med; 2019 Oct; 157():52-58. PubMed ID: 31522030
[TBL] [Abstract][Full Text] [Related]
19. House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study.
Chang AH; Polesky A; Bhatia G
BMC Public Health; 2013 Sep; 13():894. PubMed ID: 24073620
[TBL] [Abstract][Full Text] [Related]
20. Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital.
Chung SJ; Lee H; Koo GW; Min JH; Yeo Y; Park DW; Park TS; Moon JY; Kim SH; Kim TH; Sohn JW; Yoon HJ
Sci Rep; 2020 Apr; 10(1):6462. PubMed ID: 32296096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
